Mandatory use of confirmation stage with Chlamydiazyme during urinary sediment analysis

J R Anderson, G Mumtaz, P Mulhare, J Poddar, G L Ridgway

Abstract
Aims—To assess whether false positive results found when the first stage Chlamydiazyme test is performed on urinary sediment could be reduced by using the more specific second stage blocking assay.

Methods—Sediment from 173 urine samples from patients with suspected urinary tract infection caused by Gram negative bacteria and 23 control urine samples were tested using the Chlamydiazyme assay system, which included a blocking assay.

Results—A reaction result with the first stage Chlamydiazyme assay test was seen in 102 (58.9%) of the test urine samples. First stage reactivity was not blocked by the Chlamydiazyme confirmatory assay performed on repeat testing. All were correctly identified as true negative (first test false positive) results.

Conclusions—Use of a second (specific) blocking assay for the analysis of urinary sediment using Chlamydiazyme eliminates false positive results in Gram negative urinary tract infections.

(J Clin Pathol 1993;46:896–897)

A variety of enzyme immunoassays (EIA) have become available for the diagnosis of Chlamydia trachomatis infections in clinical specimens. EIAs vary in specificity and sensitivity depending on the site from which the specimen is taken, and the prevalence of C trachomatis in the clinic from which samples are received. They remain attractive techniques because they are fast, ideally suited to processing large numbers of specimens, and amenable to automation. One recurrent problem in the use of EIAs for the diagnosis of chlamydial infections has been that a wide variety of organisms (both Gram positive and Gram negative bacteria and viruses) may produce false positive results.1–4 This has special relevance to urinary sediment analysis as many organisms capable of causing false positive EIA results may also give rise to urinary tract infections. A recently published paper suggested that the Chlamydiazyme system (Abbott Diagnostic Laboratories, Chicago, USA) was unsuitable for diagnosing C trachomatis infection by urinary sediment analysis as the false positive result rate was unacceptably high in the presence of such organisms.5 This study, however, did not use the second highly specific confirmatory test to attempt verification of results.6 We therefore decided to assess whether the false positive results found when the first stage Chlamydiazyme test is performed on urinary sediment could be reduced by using the more specific second stage blocking assay.

Methods
Test urine sediments (n = 173) were selected from urine samples sent to our laboratory for the investigation of possible urinary tract infection. A growth of greater than 10⁴ organisms/ml of a probable Gram negative organism was required for a urine sample to be eligible for the study. Organism identification was confirmed using normal laboratory methods on the same day that the Chlamydiazyme assay was being run, and subsequently noted. Control urine samples were selected at random from those sent to our laboratory for pregnancy testing but with no history of urinary symptoms. A sample of each control urine sample was plated on to cysteine lactose electrolyte deficient agar (CLED; Oxoid) to check for bacterial contamination or undiagnosed urinary tract infection.

A 5–10 ml aliquot (depending on the initial volume available) of each urine sample was centrifuged at 3000 rpm for 15 minutes and the supernatant fluid discarded. The pellet was stored at 4°C for not more than 18 hours until the Chlamydiazyme first stage test was performed. The pellet was resuspended in 1 ml of phosphate buffered saline and an aliquot of suspension processed according to the manufacturer’s instruction. Incubations were performed in a Commander dynamic incubator (Abbott Diagnostic Laboratories); washings and colour reading were performed automatically using a Commander parallel processing centre (Abbott Diagnostic Laboratories).

If a pellet was found to give a positive or equivocal result with the first stage test, a further aliquot of suspension was processed for the confirmatory test according to the manufacturer’s instructions.

Results
Test urine samples were found to give reactive results in 102 of 173 (58.9%) cases with the first stage Chlamydiazyme test. First stage reactivity was not blocked by the confirmatory test for any of the urine samples tested,
Mandatory use of confirmation stage with Chlamydiazyme during urinary sediment analysis

<table>
<thead>
<tr>
<th>Identified organism</th>
<th>Total No of isolates</th>
<th>No of isolates showing first stage reactivity</th>
<th>% isolates showing first stage reactivity</th>
<th>% first stage reactive isolates blocked with confirmatory test</th>
</tr>
</thead>
<tbody>
<tr>
<td>E. coli</td>
<td>123</td>
<td>76</td>
<td>62</td>
<td>0</td>
</tr>
<tr>
<td>Klebsiella spp</td>
<td>11</td>
<td>11</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>Proteus spp</td>
<td>9</td>
<td>4</td>
<td>44</td>
<td>0</td>
</tr>
<tr>
<td>Enterobacter spp</td>
<td>13</td>
<td>4</td>
<td>31</td>
<td>0</td>
</tr>
<tr>
<td>Serratia sp</td>
<td>7</td>
<td>4</td>
<td>57</td>
<td>0</td>
</tr>
<tr>
<td>MDS</td>
<td>1</td>
<td>1</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>Citrobacter</td>
<td>3</td>
<td>3</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>Xanthomonas sp</td>
<td>1</td>
<td>1</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>Providencia sp</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Aerobacter aerogenes</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Enterococcus sp</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Candida sp</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

*Mixed growth of doubtful importance—that is, >10^3 organisms/ml and >two colonial types.

hence all were ultimately recognised as true negative results.

Control urine samples gave reactive results in two of 23 (6·9%) cases. The two with reactive results were both from urine samples submitted to the laboratory for pregnancy testing. One yielded more than 10^4 Escherichia coli/ml and the other showed a profuse mixed growth of doubtful clinical relevance. In both cases the confirmatory Chlamydiazyme test failed to block colour production, hence both were recognised as true negative results.

The organisms isolated from culture positive urine samples, together with the preliminary and confirmatory Chlamydiazyme test results are shown in the table. Two urine samples yielded a heavy growth of two Gram negative organisms. Neither of these were reactive on preliminary Chlamydiazyme testing. Three urine samples (including one of the control urine samples showing bacterial growth) showed a heavy mixed growth of doubtful clinical importance. One of these was reactive on preliminary testing but was not blocked with the second assay. The percentage of isolates producing first stage reactivity with the Chlamydiazyme assay varied between 0 and 100%, depending on the identity of the organism.

Organisms isolated included E. coli, Klebsiella sp, Pseudomonas sp, Proteus sp, Enterobacter sp, Serratia sp, Xanthomonas sp, and Aeromonas sp. The percentages of organisms giving a reactive preliminary Chlamydiazyme test are shown in the table.

There was no relation between urine volume centrifuged and enzyme linked immunosorbent assay (ELISA) value within the range of urine volumes tested (5–10 ml).

Discussion

Our results for Chlamydiazyme first stage reactivity agree with previous results obtained on urinary sediments.\(^2\)\(^3\) Specificity for the Chlamydiazyme preliminary test was calculated as 41% (71 of 173). In contrast to Demai et al.,\(^4\)\(^5\)\(^6\) we also used the confirmatory Chlamydiazyme test. The confirmatory test was introduced to improve the specificity of the original Chlamydiazyme test,\(^4\) and uses a murine monoclonal antibody directed against C trachomatis lipopolysaccharides. The use of the confirmatory test eliminated false positive reactions caused by urinary bacteria. This is important if urine samples are to be used as a screening procedure in male patients.

If urinary sediment testing were to become a routine diagnostic test (for male patients attending STD clinics, for instance), then any first stage reactive results using the Chlamydiazyme test could easily be checked using the confirmatory test as part of routine laboratory procedure. It should be appreciated that in practice the number of patients with urinary tract infections would be low and the percentage of samples in which bacterial growth was sufficient to produce false positive results would be even lower. Provided the confirmatory test is used, the specificity of the Chlamydiazyme system is satisfactory for testing urine sediments for the presence of C trachomatis.

The choice of technique(s) and kits for diagnosis of C trachomatis in routine samples also has financial implications. Culture is slow, labour intensive, and expensive. Immunofluorescence is less slow but is still labour intensive and relatively expensive. Neither of these techniques is especially suitable for first screening large numbers of specimens. Testing with EIA is likely to remain the “first line” screening method for diagnostic centres and the choice of a suitable kit is of fundamental importance. It is clear from our results that if urine sediments are to be assayed using Chlamydiazyme then the second stage test is mandatory, as the risk of a false positive result is much too high if only the first stage test is used.


Downloaded from http://jcp.bmj.com/ on August 15, 2017 - Published by group.bmj.com
Mandatory use of confirmation stage with Chlamydiazyme during urinary sediment analysis.

J R Anderson, G Mumtaz, P Mulhare, J Poddar and G L Ridgway

J Clin Pathol 1993 46: 896-897
doi: 10.1136/jcp.46.10.896

Updated information and services can be found at:
http://jcp.bmj.com/content/46/10/896

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/